Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls

Adele Green; V. Beral; R. Doll; C. Hermon; R. Peto; G. Reeves; L. Brinton; A. C. Green; P. Marchbanks; E. Negri; R. Ness; P. Peeters; M. Vessey; E. E. Calle; C. Rodriguez; L. Dal Maso; R. Talamini; D. Cramer; S. E. Hankinson; S. S. Tworoger; A. Chetrit; G. Hirsh-Yechezkel; F. Lubin; S. Sadetzki; P. Appleby; E. Banks; A. Berrington de Gonzalez; D. Bull; B. Crossley; A. Goodill; I. Green; J. Green; T. Key; R. Collins; C. A. Gonzalez; N. Lee; H. W. Ory; H. B. Peterson; P. A. Wingo; N. Martin; T. Pardthaisong; S. Silpisornkosol; C. Theetranont; B. Boosiri; S. Chutivongse; P. Jimakorn; P. Virutamasen; C. Wongsrichanalai; L. Titus-Ernstoff; B. J. Mosgaard; D. Yeates; J. Chang-Claude; M. A. Rossing; D. Thomas; N. Weiss; S. Franceschi; C. La Vecchia; H. O. Adami; C. Magnusson; T. Riman; E. Weiderpass; A. Wolk; L. A. Brinton; D. M. Freedman; P. Hartge; J. M. Lacey; R. Hoover; L. J. Schouten; P. A. van den Brandt; N. Chantarakul; S. Koetsawang; D. Rachawat; S. Graff-Iversen; R. Selmer; C. J. Bain; D. M. Purdie; V. Siskind; P. M. Webb; S. E. McCann; P. Hannaford; C. Kay; C. W. Binns; A. H. Lee; M. Zhang; P. Nasca; P. F. Coogan; L. Rosenberg; J. Kelsey; R. Paffenbarger; A. Whittemore; K. Katsouyanni; A. Trichopoulou; D. Trichopoulos; A. Tzonou; A. Dabancens; L. Martinez; R. Molina; O. Salas; M. T. Goodman; G. Laurie; M. E. Carney; L. R. Wilkens; A. Bladstrom; H. Olsson; R. B. Ness; J. A. Grisso; M. Morgan; J. E. Wheeler; J. Casagrande; M. C. Pike; R. K. Ross; A. H. Wu; M. Kumle; E. Lund; L. McGowan; X. O. Shu; W. Zheng; T. M M Farley; S. Holck; O. Meirik; H. A. Risch

doi:10.1016/S0140-6736(08)60167-1

Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls

Adele Green, V. Beral, R. Doll, C. Hermon, R. Peto, G. Reeves, L. Brinton, A. C. Green, P. Marchbanks, E. Negri, R. Ness, P. Peeters, M. Vessey, E. E. Calle, C. Rodriguez, L. Dal Maso, R. Talamini, D. Cramer, S. E. Hankinson, S. S. TworogerA. Chetrit, G. Hirsh-Yechezkel, F. Lubin, S. Sadetzki, P. Appleby, E. Banks, A. Berrington de Gonzalez, D. Bull, B. Crossley, A. Goodill, I. Green, J. Green, T. Key, R. Collins, C. A. Gonzalez, N. Lee, H. W. Ory, H. B. Peterson, P. A. Wingo, N. Martin, T. Pardthaisong, S. Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai, L. Titus-Ernstoff, B. J. Mosgaard, D. Yeates, J. Chang-Claude, M. A. Rossing, D. Thomas, N. Weiss, S. Franceschi, C. La Vecchia, H. O. Adami, C. Magnusson, T. Riman, E. Weiderpass, A. Wolk, L. A. Brinton, D. M. Freedman, P. Hartge, J. M. Lacey, R. Hoover, L. J. Schouten, P. A. van den Brandt, N. Chantarakul, S. Koetsawang, D. Rachawat, S. Graff-Iversen, R. Selmer, C. J. Bain, D. M. Purdie, V. Siskind, P. M. Webb, S. E. McCann, P. Hannaford, C. Kay, C. W. Binns, A. H. Lee, M. Zhang, P. Nasca, P. F. Coogan, L. Rosenberg, J. Kelsey, R. Paffenbarger, A. Whittemore, K. Katsouyanni, A. Trichopoulou, D. Trichopoulos, A. Tzonou, A. Dabancens, L. Martinez, R. Molina, O. Salas, M. T. Goodman, G. Laurie, M. E. Carney, L. R. Wilkens, A. Bladstrom, H. Olsson, R. B. Ness, J. A. Grisso, M. Morgan, J. E. Wheeler, J. Casagrande, M. C. Pike, R. K. Ross, A. H. Wu, M. Kumle, E. Lund, L. McGowan, X. O. Shu, W. Zheng, T. M M Farley, S. Holck, O. Meirik, H. A. Risch

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects. Methods: Individual data for 23 257 women with ovarian cancer (cases) and 87 303 without ovarian cancer (controls) from 45 epidemiological studies in 21 countries were checked and analysed centrally. The relative risk of ovarian cancer in relation to oral contraceptive use was estimated, stratifying by study, age, parity, and hysterectomy. Findings: Overall 7308 (31%) cases and 32 717 (37%) controls had ever used oral contraceptives, for average durations among users of 4·4 and 5·0 years, respectively. The median year of cancer diagnosis was 1993, when cases were aged an average of 56 years. The longer that women had used oral contraceptives, the greater the reduction in ovarian cancer risk (p

Original language	English
Pages (from-to)	303-314
Number of pages	11
Journal	The Lancet
Volume	371
Issue number	9609
DOIs	https://doi.org/10.1016/S0140-6736(08)60167-1
Publication status	Published - 26 Jan 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(08)60167-1

Cite this

Green, A., Beral, V., Doll, R., Hermon, C., Peto, R., Reeves, G., Brinton, L., Green, A. C., Marchbanks, P., Negri, E., Ness, R., Peeters, P., Vessey, M., Calle, E. E., Rodriguez, C., Dal Maso, L., Talamini, R., Cramer, D., Hankinson, S. E., ... Risch, H. A. (2008). Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. The Lancet, 371(9609), 303-314. https://doi.org/10.1016/S0140-6736(08)60167-1

@article{6c49ce744536467eb50fc6dcf0932219,

title = "Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls",

abstract = "Background: Oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects. Methods: Individual data for 23 257 women with ovarian cancer (cases) and 87 303 without ovarian cancer (controls) from 45 epidemiological studies in 21 countries were checked and analysed centrally. The relative risk of ovarian cancer in relation to oral contraceptive use was estimated, stratifying by study, age, parity, and hysterectomy. Findings: Overall 7308 (31%) cases and 32 717 (37%) controls had ever used oral contraceptives, for average durations among users of 4·4 and 5·0 years, respectively. The median year of cancer diagnosis was 1993, when cases were aged an average of 56 years. The longer that women had used oral contraceptives, the greater the reduction in ovarian cancer risk (p",

author = "Adele Green and V. Beral and R. Doll and C. Hermon and R. Peto and G. Reeves and L. Brinton and Green, {A. C.} and P. Marchbanks and E. Negri and R. Ness and P. Peeters and M. Vessey and Calle, {E. E.} and C. Rodriguez and {Dal Maso}, L. and R. Talamini and D. Cramer and Hankinson, {S. E.} and Tworoger, {S. S.} and A. Chetrit and G. Hirsh-Yechezkel and F. Lubin and S. Sadetzki and P. Appleby and E. Banks and {de Gonzalez}, {A. Berrington} and D. Bull and B. Crossley and A. Goodill and I. Green and J. Green and T. Key and R. Collins and Gonzalez, {C. A.} and N. Lee and Ory, {H. W.} and Peterson, {H. B.} and Wingo, {P. A.} and N. Martin and T. Pardthaisong and S. Silpisornkosol and C. Theetranont and B. Boosiri and S. Chutivongse and P. Jimakorn and P. Virutamasen and C. Wongsrichanalai and L. Titus-Ernstoff and Mosgaard, {B. J.} and D. Yeates and J. Chang-Claude and Rossing, {M. A.} and D. Thomas and N. Weiss and S. Franceschi and {La Vecchia}, C. and Adami, {H. O.} and C. Magnusson and T. Riman and E. Weiderpass and A. Wolk and Brinton, {L. A.} and Freedman, {D. M.} and P. Hartge and Lacey, {J. M.} and R. Hoover and Schouten, {L. J.} and {van den Brandt}, {P. A.} and N. Chantarakul and S. Koetsawang and D. Rachawat and S. Graff-Iversen and R. Selmer and Bain, {C. J.} and Purdie, {D. M.} and V. Siskind and Webb, {P. M.} and McCann, {S. E.} and P. Hannaford and C. Kay and Binns, {C. W.} and Lee, {A. H.} and M. Zhang and P. Nasca and Coogan, {P. F.} and L. Rosenberg and J. Kelsey and R. Paffenbarger and A. Whittemore and K. Katsouyanni and A. Trichopoulou and D. Trichopoulos and A. Tzonou and A. Dabancens and L. Martinez and R. Molina and O. Salas and Goodman, {M. T.} and G. Laurie and Carney, {M. E.} and Wilkens, {L. R.} and A. Bladstrom and H. Olsson and Ness, {R. B.} and Grisso, {J. A.} and M. Morgan and Wheeler, {J. E.} and J. Casagrande and Pike, {M. C.} and Ross, {R. K.} and Wu, {A. H.} and M. Kumle and E. Lund and L. McGowan and Shu, {X. O.} and W. Zheng and Farley, {T. M M} and S. Holck and O. Meirik and Risch, {H. A.}",

year = "2008",

month = jan,

day = "26",

doi = "10.1016/S0140-6736(08)60167-1",

language = "English",

volume = "371",

pages = "303--314",

journal = "The Lancet",

issn = "0140-6736",

publisher = "The Lancet",

number = "9609",

}

Green, A, Beral, V, Doll, R, Hermon, C, Peto, R, Reeves, G, Brinton, L, Green, AC, Marchbanks, P, Negri, E, Ness, R, Peeters, P, Vessey, M, Calle, EE, Rodriguez, C, Dal Maso, L, Talamini, R, Cramer, D, Hankinson, SE, Tworoger, SS, Chetrit, A, Hirsh-Yechezkel, G, Lubin, F, Sadetzki, S, Appleby, P, Banks, E, de Gonzalez, AB, Bull, D, Crossley, B, Goodill, A, Green, I, Green, J, Key, T, Collins, R, Gonzalez, CA, Lee, N, Ory, HW, Peterson, HB, Wingo, PA, Martin, N, Pardthaisong, T, Silpisornkosol, S, Theetranont, C, Boosiri, B, Chutivongse, S, Jimakorn, P, Virutamasen, P, Wongsrichanalai, C, Titus-Ernstoff, L, Mosgaard, BJ, Yeates, D, Chang-Claude, J, Rossing, MA, Thomas, D, Weiss, N, Franceschi, S, La Vecchia, C, Adami, HO, Magnusson, C, Riman, T, Weiderpass, E, Wolk, A, Brinton, LA, Freedman, DM, Hartge, P, Lacey, JM, Hoover, R, Schouten, LJ, van den Brandt, PA, Chantarakul, N, Koetsawang, S, Rachawat, D, Graff-Iversen, S, Selmer, R, Bain, CJ, Purdie, DM, Siskind, V, Webb, PM, McCann, SE, Hannaford, P, Kay, C, Binns, CW, Lee, AH, Zhang, M, Nasca, P, Coogan, PF, Rosenberg, L, Kelsey, J, Paffenbarger, R, Whittemore, A, Katsouyanni, K, Trichopoulou, A, Trichopoulos, D, Tzonou, A, Dabancens, A, Martinez, L, Molina, R, Salas, O, Goodman, MT, Laurie, G, Carney, ME, Wilkens, LR, Bladstrom, A, Olsson, H, Ness, RB, Grisso, JA, Morgan, M, Wheeler, JE, Casagrande, J, Pike, MC, Ross, RK, Wu, AH, Kumle, M, Lund, E, McGowan, L, Shu, XO, Zheng, W, Farley, TMM, Holck, S, Meirik, O & Risch, HA 2008, 'Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls', The Lancet, vol. 371, no. 9609, pp. 303-314. https://doi.org/10.1016/S0140-6736(08)60167-1

TY - JOUR

T1 - Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls

AU - Green, Adele

AU - Beral, V.

AU - Doll, R.

AU - Hermon, C.

AU - Peto, R.

AU - Reeves, G.

AU - Brinton, L.

AU - Green, A. C.

AU - Marchbanks, P.

AU - Negri, E.

AU - Ness, R.

AU - Peeters, P.

AU - Vessey, M.

AU - Calle, E. E.

AU - Rodriguez, C.

AU - Dal Maso, L.

AU - Talamini, R.

AU - Cramer, D.

AU - Hankinson, S. E.

AU - Tworoger, S. S.

AU - Chetrit, A.

AU - Hirsh-Yechezkel, G.

AU - Lubin, F.

AU - Sadetzki, S.

AU - Appleby, P.

AU - Banks, E.

AU - de Gonzalez, A. Berrington

AU - Bull, D.

AU - Crossley, B.

AU - Goodill, A.

AU - Green, I.

AU - Green, J.

AU - Key, T.

AU - Collins, R.

AU - Gonzalez, C. A.

AU - Lee, N.

AU - Ory, H. W.

AU - Peterson, H. B.

AU - Wingo, P. A.

AU - Martin, N.

AU - Pardthaisong, T.

AU - Silpisornkosol, S.

AU - Theetranont, C.

AU - Boosiri, B.

AU - Chutivongse, S.

AU - Jimakorn, P.

AU - Virutamasen, P.

AU - Wongsrichanalai, C.

AU - Titus-Ernstoff, L.

AU - Mosgaard, B. J.

AU - Yeates, D.

AU - Chang-Claude, J.

AU - Rossing, M. A.

AU - Thomas, D.

AU - Weiss, N.

AU - Franceschi, S.

AU - La Vecchia, C.

AU - Adami, H. O.

AU - Magnusson, C.

AU - Riman, T.

AU - Weiderpass, E.

AU - Wolk, A.

AU - Brinton, L. A.

AU - Freedman, D. M.

AU - Hartge, P.

AU - Lacey, J. M.

AU - Hoover, R.

AU - Schouten, L. J.

AU - van den Brandt, P. A.

AU - Chantarakul, N.

AU - Koetsawang, S.

AU - Rachawat, D.

AU - Graff-Iversen, S.

AU - Selmer, R.

AU - Bain, C. J.

AU - Purdie, D. M.

AU - Siskind, V.

AU - Webb, P. M.

AU - McCann, S. E.

AU - Hannaford, P.

AU - Kay, C.

AU - Binns, C. W.

AU - Lee, A. H.

AU - Zhang, M.

AU - Nasca, P.

AU - Coogan, P. F.

AU - Rosenberg, L.

AU - Kelsey, J.

AU - Paffenbarger, R.

AU - Whittemore, A.

AU - Katsouyanni, K.

AU - Trichopoulou, A.

AU - Trichopoulos, D.

AU - Tzonou, A.

AU - Dabancens, A.

AU - Martinez, L.

AU - Molina, R.

AU - Salas, O.

AU - Goodman, M. T.

AU - Laurie, G.

AU - Carney, M. E.

AU - Wilkens, L. R.

AU - Bladstrom, A.

AU - Olsson, H.

AU - Ness, R. B.

AU - Grisso, J. A.

AU - Morgan, M.

AU - Wheeler, J. E.

AU - Casagrande, J.

AU - Pike, M. C.

AU - Ross, R. K.

AU - Wu, A. H.

AU - Kumle, M.

AU - Lund, E.

AU - McGowan, L.

AU - Shu, X. O.

AU - Zheng, W.

AU - Farley, T. M M

AU - Holck, S.

AU - Meirik, O.

AU - Risch, H. A.

PY - 2008/1/26

Y1 - 2008/1/26

N2 - Background: Oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects. Methods: Individual data for 23 257 women with ovarian cancer (cases) and 87 303 without ovarian cancer (controls) from 45 epidemiological studies in 21 countries were checked and analysed centrally. The relative risk of ovarian cancer in relation to oral contraceptive use was estimated, stratifying by study, age, parity, and hysterectomy. Findings: Overall 7308 (31%) cases and 32 717 (37%) controls had ever used oral contraceptives, for average durations among users of 4·4 and 5·0 years, respectively. The median year of cancer diagnosis was 1993, when cases were aged an average of 56 years. The longer that women had used oral contraceptives, the greater the reduction in ovarian cancer risk (p

AB - Background: Oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects. Methods: Individual data for 23 257 women with ovarian cancer (cases) and 87 303 without ovarian cancer (controls) from 45 epidemiological studies in 21 countries were checked and analysed centrally. The relative risk of ovarian cancer in relation to oral contraceptive use was estimated, stratifying by study, age, parity, and hysterectomy. Findings: Overall 7308 (31%) cases and 32 717 (37%) controls had ever used oral contraceptives, for average durations among users of 4·4 and 5·0 years, respectively. The median year of cancer diagnosis was 1993, when cases were aged an average of 56 years. The longer that women had used oral contraceptives, the greater the reduction in ovarian cancer risk (p

U2 - 10.1016/S0140-6736(08)60167-1

DO - 10.1016/S0140-6736(08)60167-1

M3 - Article

SN - 0140-6736

VL - 371

SP - 303

EP - 314

JO - The Lancet

JF - The Lancet

IS - 9609

ER -

Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this